Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

Experimental Hematology

Volumn 40, Issue 9, 2012, Pages

  Jalkanen, Sari E ^a   Lahesmaa Korpinen, Anna Maria ^b   Heckman, Caroline A ^b   Rantanen, Ville ^b   Porkka, Kimmo ^a   Hautaniemi, Sampsa ^b   Mustjoki, Satu ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FOCAL ADHESION KINASE 2; HEAT SHOCK PROTEIN 27; HEMATOPOIETIC CELL KINASE; IMATINIB; INTERFERON; ONCOPROTEIN; PAXILLIN; PHOSPHOLIPASE C GAMMA1; PHOSPHOPROTEIN; PROTEIN C JUN; PROTEIN GSK ALPHA BETA; PROTEIN KINASE B; PROTEIN P53; PROTEIN P70; PROTEIN RSK 1; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; LEUKEMIA CELL LINE; MALE; MONONUCLEAR CELL; PREDICTION; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84865005750     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.05.010     Document Type: Article

References (53)

1. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350.
2. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
3. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
4. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
5. Baccarani M., Castagnetti F., Gugliotta G., Palandri F., Soverini S. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol 2009, 22:331-341.
6. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
7. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
8. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in " good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
9. Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850-858.
10. Hasford J., Baccarani M., Hoffmann V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011, 118:686-692.
11. Zheng C., Li L., Haak M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006, 20:1028-1034.
12. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
13. Villuendas R., Steegmann J.L., Pollan M., et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006, 20:1047-1054.
14. McLean L.A., Gathmann I., Capdeville R., Polymeropoulos M.H., Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004, 10:155-165.
15. Yong A.S., Szydlo R.M., Goldman J.M., Apperley J.F., Melo J.V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006, 107:205-212.
16. Mohty M., Yong A.S., Szydlo R.M., Apperley J.F., Melo J.V. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007, 110:380-383.
17. Guillem V., Amat P., Cervantes F., et al. Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leuk Res 2012, 36:174-181.
18. Crossman L.C., Mori M., Hsieh Y.C., et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005, 90:459-464.
19. White D.L., Dang P., Engler J., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010, 28:2761-2767.
20. Dulucq S., Bouchet S., Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
21. Marin D., Gabriel I.H., Ahmad S., et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012, 26:296-302.
22. Ovaska K., Laakso M., Haapa-Paananen S., et al. Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med 2010, 2:65.
23. Jiang Y., Zhao R.C., Verfaillie C.M. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci U S A 2000, 97:10538-10543.
24. Chu S., McDonald T., Bhatia R. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors. Leukemia 2010, 24:779-787.
25. Ilaria R.L., Van Etten R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271:31704-31710.
26. Chai S.K., Nichols G.L., Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997, 159:4720-4728.
27. Shuai K., Halpern J., ten Hoeve J., Rao X., Sawyers C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13:247-254.
28. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
29. Jalkanen S.E., Vakkila J., Kreutzman A., Nieminen J.K., Porkka K., Mustjoki S. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. Exp Hematol 2011, 39. 102-113. e101.
30. Warsch W., Kollmann K., Eckelhart E., et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011, 117:3409-3420.
31. Gutierrez-Castellanos S., Cruz M., Rabelo L., Godinez R., Reyes-Maldonado E., Riebeling-Navarro C. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Eur J Haematol 2004, 72:231-238.
32. Markova B., Albers C., Breitenbuecher F., et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 2010, 29:739-751.
33. Stanglmaier M., Warmuth M., Kleinlein I., Reis S., Hallek M. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003, 17:283-289.
34. Lionberger J.M., Wilson M.B., Smithgall T.E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000, 275:18581-18585.
35. Pene-Dumitrescu T., Smithgall T.E. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 2010, 285:21446-21457.
36. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
37. Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
38. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
39. Salesse S., Verfaillie C.M. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML. Oncogene 2002, 21:8605-8611.
40. Salgia R., Uemura N., Okuda K., et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995, 270:29145-29150.
41. Salesse S., Dylla S.J., Verfaillie C.M. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia 2004, 18:727-733.
42. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
43. Nagao R., Ashihara E., Kimura S., et al. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65-a novel Wnt/beta-catenin signaling inhibitor. Cancer Lett 2011, 312:91-100.
44. Kostenko S., Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 2009, 66:3289-3307.
45. Wang F., Zhang P., Shi C., Yang Y., Qin H. Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol 2011 Aug 23, [Epub ahead of print].
46. Kurahashi T., Miyake H., Hara I., Fujisawa M. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol 2007, 177:757-761.
47. Foster C.S., Dodson A.R., Ambroisine L., et al. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer 2009, 101:1137-1144.
48. Kapranos N., Kominea A., Konstantinopoulos P.A., et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 2002, 128:426-432.
49. Feng J.T., Liu Y.K., Song H.Y., et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005, 5:4581-4588.
50. Thanner F., Sutterlin M.W., Kapp M., et al. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res. 2005, 25:1649-1653.
51. Sedlackova L., Spacek M., Holler E., Imryskova Z., Hromadnikova I. Heat-shock protein expression in leukemia. Tumour Biol 2011, 32:33-44.
52. Dempsey N.C., Leoni F., Ireland H.E., Hoyle C., Williams J.H. Differential heat shock protein localization in chronic lymphocytic leukemia. J Leukoc Biol 2010, 87:467-476.
53. Thomas X., Campos L., Mounier C., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005, 29:1049-1058.